Highest-materiality recent filing
Bankruptcy court approved asset sale bidding procedures; bid deadline Aug 4, auction Aug 10, sale hearing Aug 20.
Filed voluntary Chapter 11 petition (Case No. 26-10989) on June 24, 2026.
Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas
Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.
Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.
Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB
Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.
Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026
Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.
Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing
Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).
Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants
Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.
Sangamo reports ~$20.9M preliminary cash; CFO terminates, interim CFO appointed
Preliminary cash and cash equivalents as of Dec 31, 2025: ~$20.9 million (unaudited, subject to change).
Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path
FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.
Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment
Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.
Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price
Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.
CFO Duraibabu resigns effective Oct 1, 2025; transitions to part-time principal financial officer role.
Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025
Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.
Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026
Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.
Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M
Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.
Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026
Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.
Sangamo Therapeutics raises ~$23M in underwritten public offering of common stock and warrants
Offering of 12.2M shares and pre-funded warrants for 34.4M shares, each with accompanying purchase warrant, at $0.50 unit price.
Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure
On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.
Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval
FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.
33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.
Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost
Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.
Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved
Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).
Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.
Sangamo files to validate share increase; stockholder challenge; hearing Dec 12
Stockholder lawsuit claims wrong voting standard for share increase; company seeks validation.
Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B
Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.
Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis
AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.
Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024
Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.
Sangamo receives Nasdaq deficiency notice for bid price below $1 per share
Notice received April 24, 2024; stock closed below $1 for 30 consecutive business days.
Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants
Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.
Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024
Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).
Sangamo: ST-920 gene therapy shows sustained efficacy; defers Phase 3 pending partnership
As of Sep 19, 2023 cutoff, 24 patients dosed; all 12 withdrawn from ERT remain off ERT with sustained supraphysiological α-Gal A activity.
Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise
Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.
Sangamo/Pfizer Alta study: 4-year data shows mean ABR 1.4, sustained FVIII activity
Cohort 4 (3e13 vg/kg) mean ABR 1.4, median 0.0; 3 of 5 participants had zero bleeds post-infusion.
Single infusion of giroctocogene fitelparvovec (3e13 vg/kg) maintains FVIII activity in mild-to-normal range through up to 208 weeks.
Sangamo reports Q3 net loss $104.2M, cuts 40% of workforce, focuses on neurology
Net loss $104.2M ($0.59/share) vs $53.2M ($0.34) year ago; revenue $9.4M down from $26.5M.
Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M
Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.
Sangamo cuts 27% of US workforce, restructures toward neurology and Fabry; EVP departs
US workforce reduced by ~120 roles (~27%); expects ~$31M annualized cost savings from restructuring.
Novartis terminated collaboration (effective June 11, 2023); Sangamo loses up to $720M in milestones and royalties.
Sangamo recovers $34.4M in SVB deposits; funds moved to alternative banks
Had approximately $34.4M in deposits with Silicon Valley Bank, substantially all uninsured.
Sangamo has $34.4M in uninsured deposits at failed Silicon Valley Bank
Sangamo had approximately $34.4 million in deposits with SVB as of March 10, 2023, substantially all uninsured.
Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner
Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.
Sangamo Therapeutics expands ATM equity offering capacity by $175M to $325M total
Amendment No. 2 with Jefferies LLC adds $175M in common stock to existing at-the-market program.
BIVV003 in sickle cell disease: 3 of 4 Group 1 patients maintained HbF >30% with no severe VOCs up to 30 months.
the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023.
On December 15, 2022, the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Courtney Beers, Ph.D., and Margaret A. Horn to serve as directors of the Board until the Company’s next annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier deaths, resignations or removals.
On December 15, 2022, the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Courtney Beers, Ph.D., and Margaret A. Horn to serve as directors of the Board until the Company’s next annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier deaths, resignations or removals.
On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.
Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.
On March 28, 2022, Saira Ramasastry, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”) since June 2012, notified the Company of her decision not to stand for re-election at the Company’s annual meeting of stockholders to be held on May 24, 2022.
On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his voluntary resignation from the Board effective March 1, 2022.
On June 28, 2021, Gary H. Loeb, Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from these positions and from his employment with the Company, in each case to be effective on July 16, 2021, in order to pursue a new opportunity.
Max materiality 1.00 · Median 0.75 · Most common event other_material